Mycobacterium tuberculosis: drug resistance and future perspectives

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Tuberculosis (TB) persists as a significant global health issue.
• The emergence and spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis strains pose a serious threat to global TB control efforts.
• The resurgence of TB has intensified the need to understand antimicrobial resistance mechanisms.

Purpose of the Study:

• To review the mechanisms of action for key first- and second-line anti-TB drugs.
• To elucidate the resistance mechanisms associated with these principal antitubercular agents.
• To provide an overview of drugs currently in clinical development for TB treatment.

Main Methods:

• Literature review of established and emerging antitubercular agents.
• Analysis of the pharmacodynamics and pharmacokinetics of major anti-TB drugs.
• Summary of current drug development pipeline for tuberculosis.

Main Results:

• Detailed descriptions of the modes of action for isoniazid, ethionamide, ethambutol, D-cycloserine, rifamycins, fluoroquinolones, streptomycin, linezolid, and pyrazinamide.
• Explanation of the molecular mechanisms conferring resistance to these drugs.
• Identification of seven anti-TB drugs in various stages of clinical development.

Conclusions:

• A comprehensive understanding of drug action and resistance is vital for effective TB management.
• Despite ongoing research and development, there remains a critical need for novel antimicrobial agents to address the challenge of drug-resistant TB.
• Continued investment in TB drug discovery and development is essential to overcome this global health threat.